Philip C Mack
Overview
Explore the profile of Philip C Mack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
4185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Rolfo C, Meshulami N, Russo A, Krammer F, Garcia-Sastre A, Mack P, et al.
J Thorac Oncol
. 2021 Nov;
17(2):214-227.
PMID: 34774792
Patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
22.
Hirsch F, Redman M, Moon J, Agustoni F, Herbst R, Semrad T, et al.
Clin Lung Cancer
. 2021 Nov;
23(1):60-71.
PMID: 34753703
Background: The phase III S0819 trial investigated addition of cetuximab to first-line chemotherapy (CT) in NSCLC. Subgroup analyses suggested an OS benefit among patients with EGFR copy number gain in...
23.
Leighl N, Redman M, Rizvi N, Hirsch F, Mack P, Schwartz L, et al.
J Immunother Cancer
. 2021 Aug;
9(8).
PMID: 34429332
Introduction: S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating the immunotherapy combination of durvalumab and tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) therapy...
24.
Gettinger S, Redman M, Bazhenova L, Hirsch F, Mack P, Schwartz L, et al.
JAMA Oncol
. 2021 Jul;
7(9):1368-1377.
PMID: 34264316
Importance: Nivolumab plus ipilimumab is superior to platinum-based chemotherapy in treatment-naive advanced non-small cell lung cancer (NSCLC). Nivolumab is superior to docetaxel in advanced pretreated NSCLC. Objective: To determine whether...
25.
Riess J, Reckamp K, Frankel P, Longmate J, Kelly K, Gandara D, et al.
Clin Lung Cancer
. 2021 Jun;
22(6):541-548.
PMID: 34140248
Background: Onalespib is a novel heat shock protein 90 inhibitor (HSP90i). Previous preclinical and clinical studies with HSP90i have demonstrated activity in EGFR-mutant non-small cell lung cancer (NSCLC). This study...
26.
McCoach C, Yu A, Gandara D, Riess J, Vang D, Li T, et al.
JCO Precis Oncol
. 2021 May;
1.
PMID: 34036220
Purpose: MET dysregulation is an oncogenic driver in non-small-cell lung cancer (NSCLC), as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients with epidermal growth factor receptor...
27.
Ayers K, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, et al.
BMC Cancer
. 2021 Apr;
21(1):441.
PMID: 33882890
Background: Immune checkpoint inhibitors (ICIs) have been incorporated into various clinical oncology guidelines for systemic treatment of advanced non-small cell lung cancers (aNSCLC). However, less than 50% (and 20%) of...
28.
Veluswamy R, Mack P, Houldsworth J, Elkhouly E, Hirsch F
J Mol Diagn
. 2021 Feb;
23(5):507-520.
PMID: 33618059
Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic driver in advanced non-small cell lung cancer, occurring in approximately 30% of...
29.
Owonikoko T, Redman M, Byers L, Hirsch F, Mack P, Schwartz L, et al.
Clin Lung Cancer
. 2021 Feb;
22(3):187-194.e1.
PMID: 33583720
Purpose: This signal finding study (S1400G) was designed to evaluate the efficacy of talazoparib in advanced stage squamous cell lung cancer harboring homologous recombination repair deficiency. Patients And Methods: The...
30.
Waqar S, Redman M, Arnold S, Hirsch F, Mack P, Schwartz L, et al.
Clin Lung Cancer
. 2020 Nov;
22(3):170-177.
PMID: 33221175
Introduction: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive squamous cell carcinoma (SCC). Patients And Methods: Patients with...